Truist Securities Rates Revolution Medicines (RVMD) buy

Truist Securities keeps its buy stance on Revolution Medicines as part of a busy stretch of analyst updates, a 12.13% upside from the current price.

By EarningsIQ Research Desk · Published Jun 30, 2026, 10:01 AM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Truist Securities rated Revolution Medicines, Inc. ($RVMD) "buy" with a $210 price target on June 30, 2026.

Since the rating, $RVMD is up 1.7% after 1 week, up 2.6% after 1 month and down 5.0% to date (from the $187.28 close on Jun 30, 2026).

RVMD Revolution Medicines, Inc.

$177.96 +125.21% year to date

Daily close · Oct 16, 2026

Key Points

Truist Securities maintained its buy rating on Revolution Medicines, Inc. RVMD with a target of $210.00.
Truist Securities's $210 price target implies 12.13% upside from Revolution Medicines, Inc.'s ($RVMD) current $187.28 share price.
Shares trade near $187.28, sitting above their 200-day moving average of $140.41 while remaining below the 50-day moving average of $199.22.
The broader analyst community holds a strong buy consensus across 20 opinions, with price targets spanning up to $320.00.

Get $RVMD trade alerts by text

We text you when insiders, Congress or big funds trade $RVMD. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Revolution Medicines, Inc. alert may contain errors. Disclosures

Truist Securities Keeps Its Stance on Revolution Medicines Stock

Truist Securities reaffirmed its buy rating on Revolution Medicines, Inc. NASDAQGS RVMD, setting a price target of $210.00. This update arrives as part of a busy stretch of coverage adjustments for the clinical-stage biotech firm as Wall Street firms review their outlooks on targeted cancer therapies.

Analyst rating track record

Truist Securities vs. the S&P 500

YTD return -0.36% hypothetical

All-time return +3.38% S&P 500 +26.66%

vs. S&P 500 -23.28% behind the index

Hypothetical returns from Truist Securities's disclosed trades, not real profit or advice. How we model this.

12-month forecast

$RVMD price target

Revolution Medicines, Inc. daily closes and this analyst's $210 target. Not advice.

Where Revolution Medicines Stock Trades Right Now

Revolution Medicines shares recently changed hands at $187.28 on Tuesday. Over the past year, the shares have moved between a low of $42.18 and a high of $224.31. The stock trades above its 200-day moving average of $140.41 though it sits below its 50-day moving average of $199.22. Because the company is still focused on clinical trials and precision oncology, it does not carry a meaningful forward P/E due to lack of current profitability.

Analysts Set New Price Targets

Other Wall Street firms have also updated their views on the biotech developer in recent months. On October 16, 2026, William Blair initiated coverage with an outperform rating. A day earlier, Needham reiterated its buy rating with a $275.00 target, while RBC Capital maintained an outperform rating on October 14, 2026, pushing its target to $260.00. Truist Securities itself maintained a buy rating with a $240.00 target on October 7, 2026. Brookline Capital initiated coverage with a buy rating and a $318.00 target on September 28, 2026, and B of A Securities moved its target to $265.00 on September 21, 2026. Morgan Stanley also started coverage on September 10, 2026, with an overweight rating and a $255.00 target. Overall, the stock carries a consensus recommendation key of strong buy backed by a mean price target of $253.21 across 20 analyst opinions.

Pipeline and Focus for Revolution Medicines

Revolution Medicines is a clinical-stage precision oncology company headquartered in Redwood City, California. The firm builds targeted therapies aimed at RAS-addicted cancers through a pipeline of RAS(ON) and RAS companion inhibitors. Its candidate drugs target specific genetic variants found in solid tumors and advanced pancreatic cancer trials. These clinical developments drive the ongoing valuation discussions among equity research analysts tracking the healthcare sector.

What to Watch Next for the Company

Next, investors will look toward the company's next earnings release scheduled for November 4, 2026, for further updates on its clinical pipeline and financial position. Market participants will also monitor whether other brokerage firms adjust their targets as clinical trial milestones approach. Analyst ratings reflect individual firm perspectives and do not constitute investment advice.